Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide
The C16 treatment inhibited reactive gliosis revealed by FITC-conjugated GFAP immunofluorescent staining; traverse section through the lumbar spinal cord; bar = 100 μm. At week 8 after immunization, normal rats group (a), vehicle control rats (b), 0.5 mg (c), 1 mg/per day C16 treated EAE rats (d), and 2 mg/per day C16 treated EAE rats (e). Vehicle late treated EAE rats (f) and C16 late treated EAE rats (g) at week 2 after immunization. Vehicle late treated EAE rats (h) and C16 late treated EAE rats (i) at week 8 post-immunization. Medium and high dose C16 treatment reduced reactive gliosis (j). versus normal rats, versus vehicle control rats, and versus 0.5 mg/per day C16 treated EAE rats at week 8 after immunization. (k) Late treated C16 treatment also inhibited reactive gliosis to a certain extent. versus normal rats; versus vehicle control rats; versus C16 treated EAE rats at week 2 postimmunization group; versus vehicle control rats at week 8 after immunization.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.